STOCKHOLM, Sweden--30 Aug--PRNewswire-AsiaNet/ InfoQuest
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan(R) (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.(1) Results from this new study, SHIFT (Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology Congress(1) in Stockholm and published in The Lancet.(2)
To view the Multimedia News Release, please click:
http://multivu.prnewswire.com/mnr/prne/shift/44195/
SHIFT involved over 6,500 patients from 37 countries with moderate to severe heart failure and heart rate above 70 bpm who were followed up for an average of 23 months. The results showed that Procoralan(R) reduces the primary endpoint, a composite of cardiovascular death or hospitalisation for worsening heart failure, by 18% (p